产品说明书
TD139
 |
同义名 : | Olitigaltin;GB0-139 |
| CAS号 : | 1450824-22-2 | |
| 货号 : | A955559 | |
| 分子式 : | C28H30F2N6O8S | |
| 纯度 : | 99%+ | |
| 分子量 : | 648.635 | |
| MDL号 : | MFCD29919388 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(77.08 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 1 mg/mL(1.54 mM) 无水乙醇: 3 mg/mL(4.63 mM)，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
1% DMSO + water 0.1 mg/mL clear |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Galectins form a family of soluble lectins that take part in a wide range of biological processes, such as cell adhesion, cell migration, signaling, intracellular trafficking, cell proliferation, apoptosis, gene expression regulation, inflammation, and immune response. TD 139 is an effective and selective galectin-3 inhibitor with a Kd value of 0.036 µM and Kd values of 2.2 µM and 32 µM for galectin-1 and galectin-7, respectively. TD 139 can be used for the treatment of idiopathic pulmonary fibrosis (IPF)[1]. In primary lung alveolar epithelial cells (AECs), TD 139 (10 µM) reduced TGF-β1–induced β-catenin translocation to the nucleus, with most of the β-catenin remaining at the cell surface. In the lungs of wild-type mice treated with 10 µg TD 139, there was marked reduction in fibrosis and β-catenin activation accompanied by decreased galectin-3 expression. TD 139 produced a significant decrease in total lung collagen[2]. | ||
| 作用机制 | TD 139 interacts with the five binding subsites (A–E) that comprise the CRD (carbohydrate recognition domain) of galectin-3[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.54mL 0.31mL 0.15mL |
7.71mL 1.54mL 0.77mL |
15.42mL 3.08mL 1.54mL |
| 参考文献 |
|---|